New tuberculosis tools are here: Can we deliver them for maximal impact?  by Pai, Madhukar & Memish, Ziad A.
Journal of Epidemiology and Global Health (2013) 3, 1–2http : / / www.elsev ier .com/ locate / jeghEDITORIAL FOR WORLD TB DAY (24TH MARCH 2013)New tuberculosis tools are here: Can we deliver them
for maximal impact?24th March is World TB Day, and a good time to
take stock of progress in global tuberculosis (TB)
control. In 2013, TB continues to be major public
health threat, with an estimated 8.7 million new
cases per year, and an estimated 1.4 million deaths
from TB [1]. Early case detection and rapid treat-
ment continues to remain the most important TB
control strategy. With the incidence of TB declin-
ing very slowly, it is now obvious that TB cannot
be eliminated by 2050, at least not with the kind
of TB tests, drugs and vaccine used in most high
TB burden countries [2,3]. Currently, TB patients
are not diagnosed and cured quickly enough, and
this ensures high levels of transmission [2].
TB elimination will require substantially better
tools, and, finally, there is some light at the end
of the tunnel. New, accurate diagnostics for TB
are finally here and steadily being scaled up. For
the first time, a rapid, cartridge-based, automated
molecular test, the Xpert MTB/RIF test (Cepheid
Inc., Sunnyvale, CA), is being scaled up for TB diag-
nosis and drug-resistance detection in more than
20 countries. The Xpert MTB/RIF technology was
endorsed by the WHO in 2010 [4]. Since then, over
1,900,000 Xpert MTB/RIF cartridges have been
procured worldwide in the public sector in 77 of
the 145 countries eligible for concessional pricing
[4].
Several published studies, summarized in a re-
cent Cochrane systematic review [5], have con-
firmed the high accuracy of this test and its
superior performance vis-a`-vis the conventional
sputum smear microscopy. In June 2012, UNITAID,
the Bill and Melinda Gates Foundation, the US
Agency for International Development (USAID),
and US President’s Emergency Plan for AIDS Relief2210-6006/$ - see front matter c 2013http://dx.doi.org/10.1016/j.jegh.2013.02.001Published by Elsevier Ltd. o
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Inc. to reduce the cost of the test to $9.98 per car-
tridge (from the original price of $16.86). As part of
the agreement, UNITAID is also supporting scale-up
through an accelerated roll-out of the test in high-
burden countries via the WHO Stop TB Department
and the Stop TB Partnership secretariat. The three-
year TBXpert project will support the implementa-
tion of over 200 GeneXpert instruments and 1.4
million Xpert cartridges in 21 countries, starting
in 2013 [4].
Already, fast-follower, next-generation molecu-
lar TB tests have emerged, after the Xpert MTB/
RIF technology [6]. In many ways, the Xpert
MTB/RIF technology has become the pathfinder
for wider use of rapid, accurate molecular tests
for TB, and for showing that it is possible for
healthcare programs to go beyond the century-old
microscopy. These next-generation NAATs will help
further scale-up molecular testing in resource-lim-
ited settings and eventually replace sputum smears
in peripheral laboratories.
Progress has also been made on the TB drug
front. Recently, the US Food and Drug Administra-
tion approved a drug called bedaquiline, as part of
combination therapy to treat adults with MDR-TB
when other alternatives are not available [7]. This
is the first new TB drug approved in over 40 years.
Other new TB drugs or combinations are expected
within the next 2–3 years. For example, moxiflox-
acin has the potential to be first new drug to treat
drug-sensitive TB in nearly 50 years, and a moxi-
floxacin-containing regimen could shorten treat-
ment duration by a third. A recent trial showed
that a novel drug combination treatment (called
PaMZ) containing PA-824, moxifloxacin andn behalf of Ministry of Health, Saudi Arabia.
creativecommons.org/licenses/by-nc-nd/4.0/).
2 Editorialpyrazinamide was highly effective [8]. Although
further trials are needed, this drug combination
has the potential to treat patients with drug sensi-
tive as well as drug resistant TB. Shortening TB
treatment to 2 or even 4 months should greatly in-
crease cure rates, improve patient adherence, and
reduce the likelihood of drug resistance.
In contrast to diagnostics and drugs, progress
has been relatively slower with new TB vaccine
development, although major investments have
been made in this area. Among the various candi-
date vaccines being evaluated, results from the
trial on the MVA85A vaccine were published re-
cently [9]. Although not efficacious, this first TB
vaccine efficacy trial in almost a century has of-
fered useful insights for subsequent vaccine candi-
dates entering trials.
As we welcome the emergence of new tools for
TB, it is critical to remember that new tools, by
themselves, cannot make an impact, unless they
are successfully delivered to the millions who need
them. The availability of new tools does not mean
they will be adopted, used correctly, scaled-up, or
have public health impact.
Experience to date with new diagnostics sug-
gests that many national TB programmes (NTPs)
in high-burden countries struggle to adopt and
scale-up new tools, even when these are backed
by evidence and global policy recommendations.
As reviewed recently [10], there are several com-
mon barriers to effective national adoption and
scale-up of new technologies: global policy rec-
ommendations that do not provide sufficient
information for scale-up; complex decision-mak-
ing processes and weak political commitment at
country-level; limited engagement of and support
to NTP managers; high cost of tools and poor fit
with user needs; unregulated markets and inade-
quate business models; limited capacity for labo-
ratory strengthening and implementation
research; and insufficient advocacy and donor
support. Overcoming these barriers will require
enhanced country-level advocacy, resources,
technical assistance and political commitment.
The challenge for TB control in future will be
less about technology and more about finding inno-
vative business models for delivering technologies
in a manner that ensures impact, and at a scale
where impact is substantial.References
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